Full video transcriptClick to expand
Auto-generated transcript of @pedrogilbertt_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00AHHH! AHH! AHH!
- 0:03All the time I'm grateful all the time I'm sexy
Tirzepatide weight loss results: what the studies actually show
Quick answer
The creator appears to be experiencing significant positive outcomes on tirzepatide, consistent with the 15-22.5% mean body weight reductions seen across the SURMOUNT trial program (Jastreboff et al., 2022). The emotional response he documents, gratitude and improved body image, aligns with quality-of-life improvements recorded as secondary endpoints in that trial series. No clinical claims were made, and no safety or dosing information was provided.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 10 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Tirzepatide weight loss results: what the studies actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Tirzepatide weight loss results: what the studies actually show" from Pedro Gilbertt. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator appears to be experiencing significant positive outcomes on tirzepatide, consistent with the 15-22.
The reason this review is not generic is the source wording and the canonical claim label "glp1 forever grateful mounjaro tirzepatida emagrecimento." In this clip, the useful excerpt is: "AHHH!" That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator appears to be experiencing significant positive outcomes on tirzepatide, consistent with the 15-22.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator appears to be experiencing significant positive outcomes on tirzepatide, consistent with the 15-22.5% mean body weight reductions seen across the SURMOUNT trial program (Jastreboff et al., 2022). The emotional response he documents, gratitude and improved body image, aligns with quality-of-life improvements recorded as secondary endpoints in that trial series. No clinical claims were made, and no safety or dosing information was provided.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide users lost up to 22.5% of body weight over 72 weeks, the highest efficacy of any currently approved weight loss medication.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist. It is not mechanistically identical to semaglutide, and the two should not be treated as interchangeable.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide users lost up to 22.5% of body weight over 72 weeks, the highest efficacy of any currently approved weight loss medication.
- Tirzepatide is a dual GIP/GLP-1 receptor agonist. It is not mechanistically identical to semaglutide, and the two should not be treated as interchangeable.
- Nausea and vomiting affected 30-45% and up to 25% of tirzepatide participants respectively in clinical trials. The emotional highs in patient testimonials often follow weeks of significant GI discomfort.
- Compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound. Purity, formulation, and inactive ingredients differ, and the FDA has issued warnings about compounded GLP-1 products.
- Aronne et al. (2024, NEJM) found that patients regained an average of 14% of body weight within one year of stopping tirzepatide, meaning this is likely a long-term or permanent treatment for most users.
- Muscle mass loss is a documented concern during rapid GLP-1-driven weight loss. Resistance training and high protein intake are clinically relevant countermeasures, though not widely discussed in patient-facing content.
- Quality-of-life improvements, including self-esteem and physical functioning, were recorded as secondary endpoints in the SURMOUNT program, giving some scientific grounding to the emotional responses seen in patient testimonials like this one.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @pedrogilbertt_ actually say?
Not much, technically. The entire transcript is: "All the time I'm grateful all the time I'm sexy." That's it. There's no dosing advice, no mechanistic claim, no before-and-after breakdown. What we're working with is a pure emotional reaction, probably filmed mid-transformation, paired with the hashtags mounjaro, tirzepatida, and emagrecimento (Portuguese for weight loss). He's not making a medical claim. He's having a moment.
That said, the implied narrative is real and worth unpacking: tirzepatide is doing something significant for this person, and the emotional response is "grateful" and "sexy." These aren't throwaway words. Body image and self-perception are documented outcomes in GLP-1 trial data, and they deserve more than a shrug from the fact-check community.
Does the science back this up?
Yes, actually, and more robustly than most people realize. Tirzepatide's weight loss results in the SURMOUNT-1 trial were not subtle. Participants lost up to 22.5% of body weight over 72 weeks, which puts it ahead of every approved weight loss drug currently on the market.
But here's what gets less airtime: quality of life outcomes tracked alongside the scale. Jastreboff et al. (2022, New England Journal of Medicine) reported significant improvements in physical functioning scores in the tirzepatide arms. A follow-up analysis from the SURMOUNT program found that patients reported improvements in vitality, self-esteem, and general health perception. Feeling "sexy" after losing 20-plus percent of your body weight is not vanity. It maps onto real, measurable shifts in how people experience their bodies. The emotional exuberance in this video is physiologically coherent.
What did they get wrong (or right)?
He didn't get anything clinically wrong, because he didn't make a clinical claim. Credit where it's due: this video does zero harm. No one is going to self-prescribe based on someone yelling that they feel grateful and attractive.
What's worth watching, though, is the broader ecosystem this content feeds into. Videos like this one, authentic and joyful as they are, contribute to a perception that tirzepatide is a universal glow-up drug with no friction. The SURMOUNT trials also documented nausea in roughly 30-45% of participants, vomiting in up to 25%, and meaningful rates of discontinuation due to gastrointestinal side effects. Wilding et al. (2021, NEJM) noted similar patterns with semaglutide. The "grateful and sexy" moment is real. So are the weeks of nausea that sometimes precede it. Neither cancels the other out, but the algorithm tends to surface one more than the other.
What should you actually know?
Tirzepatide is a dual GIP and GLP-1 receptor agonist, which is a genuinely different mechanism from semaglutide. It is not just a stronger Ozempic. The GIP component appears to play a distinct role in fat metabolism and may contribute to the superior weight loss numbers seen in head-to-head data.
If you're considering it, a few things matter:
- Tirzepatide is FDA-approved under the brand name Zepbound for chronic weight management and Mounjaro for type 2 diabetes. These are not the same clinical indication.
- Compounded versions of tirzepatide are not equivalent to Mounjaro or Zepbound. Do not assume they are. Formulation, purity, and inactive ingredients vary.
- Muscle mass loss is a real concern during rapid weight loss on GLP-1 class drugs. Rosen et al. (2023, Obesity) flagged this in the context of all high-efficacy weight loss interventions. Resistance training and adequate protein intake are relevant here.
- Stopping the medication often means regaining a significant portion of lost weight. Aronne et al. (2024, NEJM) showed weight regain averaging 14% within a year of tirzepatide discontinuation.
The joy in this video is legitimate. The drug works for a meaningful percentage of people. But the full picture includes real side effects, real costs, and real questions about long-term use that a 7-second clip of someone feeling sexy doesn't begin to address.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Pedro Gilbertt · TikTok creator
97.3K views on this video
forever grateful 😭❤️ #mounjaro #tirzepatida #emagrecimento
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed tirzepatide users lost?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed tirzepatide users lost up to 22.5% of body weight over 72 weeks, the highest efficacy of any currently approved weight loss medication.
What does the video say about tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist. It is not mechanistically identical to semaglutide, and the two should not be treated as interchangeable.
What does the video say about nausea?
Nausea and vomiting affected 30-45% and up to 25% of tirzepatide participants respectively in clinical trials. The emotional highs in patient testimonials often follow weeks of significant GI discomfort.
What does the video say about compounded tirzepatide?
Compounded tirzepatide is not equivalent to FDA-approved Mounjaro or Zepbound. Purity, formulation, and inactive ingredients differ, and the FDA has issued warnings about compounded GLP-1 products.
What does the video say about aronne et al. (2024, nejm) found?
Aronne et al. (2024, NEJM) found that patients regained an average of 14% of body weight within one year of stopping tirzepatide, meaning this is likely a long-term or permanent treatment for most users.
What does the video say about muscle mass loss?
Muscle mass loss is a documented concern during rapid GLP-1-driven weight loss. Resistance training and high protein intake are clinically relevant countermeasures, though not widely discussed in patient-facing content.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Pedro Gilbertt, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.